-
Leerink: Pharmacyclics Is Now Worth $240
Tuesday, March 3, 2015 - 4:33pm | 252In a report published Monday, Leerink analysts Howard Liang and Gena Wang boosted their price target on Pharmacyclics, Inc. (NASDAQ: PCYC) shares from $204 to $240. The reason behind the increase is not only a merger rumor, but also "intriguing PDL1 combination data. "Preclinical data...
-
UPDATE: Investors Bullish On InterMune After Leerink Upgrade
Monday, May 19, 2014 - 11:50am | 93In a report issued Monday, Leerink upgraded its rating of InterMune (NASDAQ: ITMN) from Market Perform to Outperform with a target price of $41. Howard Liang of Leerink anticipates that recent developments in trials done by InterMune should provide the company with plenty of upside. Esbriet...
-
Analysts Comment on Merck's Hep C Regiment Advances
Monday, November 4, 2013 - 11:39am | 252Several analysts commented on Merck's (NYSE: MRK)'s advances on Hepatitis C cure regiment. ISI analyst Mark Schoenebaum commented that Merck's oral regimen for hepatitis C genotype 1 may be the first "truly clinical competitive" regimen against Gilead. Schoenebaum noted that this one pill per day...
-
Leerink Swann Rates Medivation (MDVN) Market Perform
Tuesday, March 16, 2010 - 8:50am | 178Leerink Swann analysts Howard Liang and Jonathan Eckard rated shares of Medivation, Inc. (Nasdaq: MDVN) a Market Perform with a valuation of $14. The analysts said that the negative readout for the Phase III CONNECTION trial for Dimebon, without any efficacy signal, leads them to believe that...